Mark Neumann
Chief Commercial Officer at Veradermics, Inc (MANE)
Mark Neumann has filed 25 insider reports with the SEC since February 2021, as chief Commercial Officer at Veradermics, Inc (MANE) and EVP and chief Commercial Officer at Intra-Cellular Therapies, Inc. (ITCI). Mark Neumann made no open-market purchases or sales in the last 12 months. The latest filing, on February 6, 2026, reports grant or award at Veradermics, Inc (MANE).
- Filings
- 25
- Companies
- 2
- Bought on market
- None
- Sold on market
- $19.3M
Companies where Mark Neumann is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| MANE Veradermics, Inc | Chief Commercial Officer | $138.78 | Feb 6, 2026 | ||||
| ITCI Intra-Cellular Therapies, Inc. | EVP, Chief Commercial Officer | 0 | $19.3M | Apr 2, 2025 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Feb 3, 2026MANESEC Form 4 filed by Chief Commercial Officer Neumann MarkForm 4Grant or award
- Apr 2, 2025ITCIEVP, Chief Commercial Officer Neumann Mark returned $6,971,052 worth of shares to the company (52,811 units at $132.00), closing all direct ownership in the companyForm 4Grant or awardSale back to the company
- Mar 10, 2025ITCIEVP, Chief Commercial Officer Neumann Mark converted options into 20,478 shares and covered exercise/tax liability with 8,688 shares, increasing direct ownership by 29% to 52,811 unitsForm 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Mar 1, 2025ITCIEVP, Chief Commercial Officer Neumann Mark covered exercise/tax liability with 3,709 shares and converted options into 8,742 shares, increasing direct ownership by 14% to 41,021 unitsForm 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Feb 3, 2025ITCIEVP, Chief Commercial Officer Neumann Mark was granted 11,017 shares and covered exercise/tax liability with 4,729 shares, increasing direct ownership by 21% to 35,988 unitsForm 4Grant or awardShares withheld for taxes or exercise price
- Aug 16, 2024-$1.41MITCIEVP, Chief Commercial Officer Neumann Mark exercised 18,714 shares at a strike of $36.89 and sold $1,405,047 worth of shares (18,714 units at $75.08)Form 4Exercise or conversion of a derivativeOpen-market sale
- Mar 11, 2024-$1.36MITCINeumann Mark sold $1,356,110 worth of shares (20,477 units at $66.23) and converted options into 7,345 shares, decreasing direct ownership by 31% to 29,700 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 6, 2024ITCINeumann Mark converted options into 13,132 shares, increasing direct ownership by 44% to 42,832 unitsForm 4Exercise or conversion of a derivative
- Mar 1, 2024ITCISEC Form 4 filed by Neumann MarkForm 4Grant or award
- Feb 26, 2024-$554KITCINeumann Mark converted options into 7,907 shares and sold $554,491 worth of shares (7,907 units at $70.13)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Feb 2, 2024-$796KITCINeumann Mark was granted 11,860 shares and sold $796,367 worth of shares (11,860 units at $67.15)Form 4Grant or awardOpen-market sale10b5-1 plan
- Nov 6, 2023-$2.36MITCINeumann Mark exercised 26,754 shares at a strike of $23.94 and sold $2,358,152 worth of shares (42,393 units at $55.63), decreasing direct ownership by 34% to 29,700 unitsForm 4Exercise or conversion of a derivativeOpen-market sale
- Aug 7, 2023-$3.25MITCISEC Form 4: Neumann Mark exercised 55,300 shares at a strike of $18.59 and sold $3,251,087 worth of shares (55,300 units at $58.79)Form 4Exercise or conversion of a derivativeOpen-market sale
- Mar 28, 2023-$847KITCISEC Form 4 filed by Neumann MarkForm 4Open-market sale10b5-1 plan
- Mar 13, 2023-$540KITCISEC Form 4: Neumann Mark was granted 16,708 shares, sold $539,599 worth of shares (12,308 units at $43.84) as part of a pre-agreed trading plan and converted options into 7,344 shares, increasing direct ownership by 24% to 60,943 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 6, 2023ITCISEC Form 4 filed by Neumann MarkForm 4Grant or award
- Feb 24, 2023-$191KITCISEC Form 4: Neumann Mark sold $190,648 worth of shares (4,046 units at $47.12) as part of a pre-agreed trading plan and converted options into 7,906 shares, increasing direct ownership by 7% to 56,440 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Feb 21, 2023-$183KITCISEC Form 4: Neumann Mark converted options into 11,139 shares and sold $183,246 worth of shares (3,898 units at $47.01) as part of a pre-agreed trading plan, increasing direct ownership by 16% to 52,580 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Apr 8, 2022-$5.56MITCISEC Form 4: Neumann Mark exercised 86,348 shares at a strike of $12.73 and sold $5,558,051 worth of shares (86,348 units at $64.37) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 10, 2022ITCISEC Form 4 filed by Neumann MarkForm 4Grant or award
- Feb 22, 2022-$616KITCISEC Form 4: Neumann Mark converted options into 11,139 shares and sold $615,827 worth of shares (11,139 units at $55.29) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jan 10, 2022-$854KITCISEC Form 4: Neumann Mark converted options into 20,948 shares and sold $854,255 worth of shares (20,948 units at $40.78) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Oct 18, 2021-$550KITCISEC Form 4: Neumann Mark sold $549,551 worth of shares (13,448 units at $40.86) as part of a pre-agreed trading plan and converted options into 13,448 sharesForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Feb 23, 2021ITCISEC Form 4 filed by Mark NeumannForm 4Grant or award
- Feb 19, 2021-$203KITCISEC Form 4: Mark Neumann exercised 11,139 units of Common Stock at a strike of $0.00 and sold $203,308 worth of Common Stock (5,184 units at $39.22), increasing ownership by 15% to 45,339 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
Compare Mark Neumann with
- Mark Neumann vs David Hollander1 shared
- Mark Neumann vs Timothy August Durso1 shared
- Mark Neumann vs Reid Alexander Waldman1 shared
- Mark Neumann vs John W Childs1 shared
- Mark Neumann vs David Matthew Friedman1 shared
- Mark Neumann vs Vlad Coric1 shared
Other insiders at the same companies
- David HollanderMANE
- Montanova Capital, LLCMANE
- Timothy August DursoMANE
- Reid Alexander WaldmanMANE
- John W ChildsMANE
- Seven Fleet Capital Management LPMANE
- Katarina PanceMANE
- Jane M. Grant-KelsMANE
- David Matthew FriedmanMANE
- Vlad CoricMANE
- Longitude Capital Partners V, LLCMANE
- Patrick G EnrightMANE
- Michael V. GrecoMANE
- Dominic Gabriel CarranoMANE
- Eduardo Rene SalasITCI
- Rory B RiggsITCI
Questions about Mark Neumann
- What is Mark Neumann's role at Veradermics, Inc?
- Mark Neumann reports to the SEC as chief Commercial Officer at Veradermics, Inc (MANE), according to the latest filing on February 6, 2026. Mark Neumann has also filed as EVP and chief Commercial Officer at Intra-Cellular Therapies, Inc. (ITCI).
- Has Mark Neumann bought or sold stock recently?
- The most recent open-market sale was on August 16, 2024: sold 18,714 shares of Intra-Cellular Therapies, Inc. (ITCI) for $1.41M at an average of $75.08.
- How do I get alerts when Mark Neumann files?
- Follow Mark Neumann on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Mark Neumann (SEC CIK 0001756211). Totals count each trade once, skipping amendments whose original is on file, from Feb 23, 2021 on. View on SEC EDGAR